Effect of immune score at initial diagnosis in predicting prognosis in patients with multiple myeloma treated with bortezomib

WEI Min; GUO Honggang; LIU Siwei; XU Fangfang; ZHANG Yin; SHI Jie; XU Zhiwei; CHEN Yuqing

doi:10.7619/jcmp.20210611

Journal of Clinical Medicine in Practice > 2021 > 25(8): 46-51. > DOI: 10.7619/jcmp.20210611

WEI Min, GUO Honggang, LIU Siwei, XU Fangfang, ZHANG Yin, SHI Jie, XU Zhiwei, CHEN Yuqing. Effect of immune score at initial diagnosis in predicting prognosis in patients with multiple myeloma treated with bortezomib[J]. Journal of Clinical Medicine in Practice, 2021, 25(8): 46-51. DOI: 10.7619/jcmp.20210611

Citation:

PDF (1191 KB)

Effect of immune score at initial diagnosis in predicting prognosis in patients with multiple myeloma treated with bortezomib

1.
People's Hospital of Henan University, Zhengzhou, Henan, 450003
2.
Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, Henan, 450003
3.
Department of Hematology, First Hospital of Peking University, Beijing, 100000

More Information

Received Date: February 03, 2021
Available Online: April 25, 2021
Published Date: April 27, 2021

Graphical Abstract

Abstract

Abstract

Objective To investigate the effect of the lymphocyte-to-monocyte ratio (LMR), uninvolved immunoglobulin (u-Ig) levels and immune scores for newly diagnosed multiple myeloma (MM) patients treated with bortezomib.
Methods The clinical data of 201 newly diagnosed MM patients was retrospectively analyzed. Patients were divided into low LMR group (LMR < 3.6) and high LMR group (LMR≥3.6) according to the cutoff value of LMR related references. According to the reduced levels of u-Ig (IgG, IgA, IgM), the patients were divided into normal u-Ig group, one index of u-Ig reduced group (one index was lower than the lower limit of normal value) and two indexes of u-Ig reduced group (two or more indicators were lower than the lower limit of normal value). Immunization groups were established, including low risk group, medium risk group and high risk group. Baseline data, objective response rate (ORR) and overall survival (OS) of patients of LMR groups and u-Ig groups before treatment were analyzed. Independent factors of poor prognosis related to OS in MM patients were analyzed.
Results The ORR of low-risk group was significantly higher than that of medium-risk group and high-risk group(P=0.044, P=0.007). Aged 65 years and above, International Staging System (ISS) stage Ⅲ, platelet ≤100×10⁹/L, lactate dehydrogenase (LDH) >250 U/L, LMR < 3.6, u-Ig decreased by one item, u-Ig decreased by ≥2 items and immunization medium risk as well as high risk were independent adverse prognostic factors affecting the OS in MM patients.
Conclusion In the application of bortezomib, the immune score has a good effect on the treatment response and prognosis of MM patients, and can be used as a reference for early identification of high-risk patients.
- multiple myeloma,
- bortezomib,
- immune,
- prognosis

FullText(HTML)

References (22)

References

[1]	COHEN A D, RAJE N, FOWLER J A, et al. How to train your T cells: overcoming immune dysfunction in multiple myeloma[J]. Clin Cancer Res, 2020, 26(7): 1541-1554. doi: 10.1158/1078-0432.CCR-19-2111
[2]	PORRATA L F, RISTOW K M, HABERMANN T M, et al. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2014, 55(12): 2728-2738. doi: 10.3109/10428194.2014.893313
[3]	王浩峰, 王耀辉, 陆劲松. 乳腺癌反映炎症状态外周血细胞间比值研究进展[J]. 中华肿瘤防治杂志, 2019, 26(8): 598-602. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201908018.htm
[4]	ROMANO A, LAURA PARRINELLO N, CERCHIONE C, et al. The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents[J]. Blood Cancer J, 2017, 7(12): 649. doi: 10.1038/s41408-017-0019-6
[5]	GAO W, LI J, JIAN Y, et al. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation[J]. Int J Hematol, 2019, 109(2): 169-174. doi: 10.1007/s12185-018-2547-7
[6]	SWEISS K, LEE J, MAHMUD N, et al. Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant[J]. Bone Marrow Transplant, 2020, 55(1): 199-206. doi: 10.1038/s41409-019-0681-3
[7]	中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2015年修订)[J]. 中华内科杂志, 2015, 54(12): 1066-1070. doi: 10.3760/cma.j.issn.0578-1426.2015.12.020
[8]	UTTERVALL K, DURU A D, LUND J, et al. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment[J]. PLoS One, 2014, 9(7): e101819. doi: 10.1371/journal.pone.0101819
[9]	钱晓丹, 姚爽玲, 管俊. 全身弥散加权成像在多发性骨髓瘤中的临床应用进展[J]. 实用临床医药杂志, 2020, 24(1): 19-23. doi: 10.7619/jcmp.202001005
[10]	PRATT G, GOODYEAR O, MOSS P. Immunodeficiency and immunotherapy in multiple myeloma[J]. Br J Haematol, 2007, 138(5): 563-579. doi: 10.1111/j.1365-2141.2007.06705.x
[11]	GÖRGVN G T, WHITEHILL G, ANDERSON J L, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans[J]. Blood, 2013, 121(15): 2975-2987. doi: 10.1182/blood-2012-08-448548
[12]	BEIDER K, BITNER H, LEIBA M, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype[J]. Oncotarget, 2014, 5(22): 11283-11296. doi: 10.18632/oncotarget.2207
[13]	DOSANI T, COVUT F, BECK R, et al. Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma[J]. Blood Cancer J, 2017, 7(6): e579. doi: 10.1038/bcj.2017.60
[14]	PRUZANSKI W, GIDON M S, ROY A. Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis[J]. Clin Immunol Immunopathol, 1980, 17(2): 280-286. doi: 10.1016/0090-1229(80)90097-5
[15]	PÉREZ-PERSONA E, VIDRIALES M B, MATEO G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells[J]. Blood, 2007, 110(7): 2586-2592. doi: 10.1182/blood-2007-05-088443
[16]	SØRRIG R, KLAUSEN T W, SALOMO M, et al. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study[J]. Eur J Haematol, 2016, 97(3): 303-309. doi: 10.1111/ejh.12728
[17]	MOORE P A, BELVEDERE O, ORR A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte Stimulator[J]. Science, 1999, 285(5425): 260-263. doi: 10.1126/science.285.5425.260
[18]	SANCHEZ E, GILLESPIE A, TANG G, et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma[J]. Clin Cancer Res, 2016, 22(13): 3383-3397. doi: 10.1158/1078-0432.CCR-15-2224
[19]	LUO R Z, LIU W L, WANG J, et al. Role of BAFF in pediatric patients with allergic rhinitis during sublingual immunotherapy[J]. Eur J Pediatr, 2014, 173(8): 1033-1040. doi: 10.1007/s00431-014-2287-5
[20]	PUGA I, CERUTTI A, COLS M. Modulación del cambio de isotipo de Las inmunoglobulinas por señales del sistema inmunitario innato[J]. Semin De La Fundación Española De Reumatología, 2014, 15(1): 11-18.
[21]	陈思言. 硼替佐米联合地塞米松和沙利度胺治疗多发性骨髓瘤的临床疗效[J]. 实用临床医药杂志, 2014, 18(17): 124-126. doi: 10.7619/jcmp.201417041
[22]	何月茹, 李振宇, 许婷, 等. 硼替佐米不同给药途径在多发性骨髓瘤治疗中的疗效与安全性分析[J]. 徐州医科大学学报, 2020, 40(3): 196-198. doi: 10.3969/j.issn.2096-3882.2020.03.009

[1]	WANG Fandong, ZHENG Jiazhuang, CHEN Yu, SONG Zhaojun, LIU Yuanbin, TANG Long, WANG Miao, ZHOU Yong, LIU Huiyi. Effects of pedicle screw internal fixation via different approaches in patients with thoracic and lumbar fractures[J]. Journal of Clinical Medicine in Practice, 2023, 27(21): 83-87. DOI: 10.7619/jcmp.20232471
[2]	YANG Yang, LIU Hao, WANG Fulin, HE Erping. Analysis of recurrence factors after borehole drainage for chronic subdural hematoma[J]. Journal of Clinical Medicine in Practice, 2020, 24(22): 73-75. DOI: 10.7619/jcmp.202022021
[3]	ZHAO Ping, ZHANG Li. Effectiveness and safety of continuous subcutaneous insulin infusion in the treatment of gestational diabetes patients[J]. Journal of Clinical Medicine in Practice, 2020, 24(15): 61-64. DOI: 10.7619/jcmp.202015017
[4]	ZHAO Yuefeng. Effect of hematoma removal and decompressive craniectomy in the treatment of hypertensive intracerebral hemorrhage[J]. Journal of Clinical Medicine in Practice, 2020, 24(6): 98-100. DOI: 10.7619/jcmp.202006027
[5]	SHI Qiang, PAN Weicheng, LIU Yue, WANG Zhikang, LI Yunjian, CHENG Yun, WEI Jingyu. Effect of surgical repair of refractory subcutaneous effusion after modified radical mastectomy for breast cancer[J]. Journal of Clinical Medicine in Practice, 2019, 23(24): 89-91. DOI: 10.7619/jcmp.201924028
[6]	HAO Caihong, MA Shicai. Nursing effect of hydrocolloid transparent dressing on reduction of stasis and pain in plateletpheresis patients with subcutaneous ecchymosis[J]. Journal of Clinical Medicine in Practice, 2019, 23(22): 20-23. DOI: 10.7619/jcmp.201922007
[7]	XU Jialu, PAN Huirong, CHANG Zheng, ZHU Min. Effects of different abdominal subcutaneous injection of low molecular weight heparin sodium[J]. Journal of Clinical Medicine in Practice, 2016, (16): 145-147. DOI: 10.7619/jcmp.201616044
[8]	HUANG Jian, XIAO Chunrong. Clinical analysis on diagnosis and treatment of 20 patients with delayed traumatic intra cephalic hematoma[J]. Journal of Clinical Medicine in Practice, 2015, (Z1): 86-87.
[9]	CHEN Qiang. Clinical research on the minimally invasive hematoma in the treatment of hypertensive thalamic hemorrhage[J]. Journal of Clinical Medicine in Practice, 2013, (21): 97-99. DOI: 10.7619/jcmp.201321027
[10]	CHEN Fu-mei. Hemodialysis patients with arteriovenous fistula puncture needle withdrawal after subcutaneous hematoma reason analysis and nursing[J]. Journal of Clinical Medicine in Practice, 2012, (14): 42-43. DOI: 10.3969/j.issn.1672-2353.2012.14.015

Cited By

Cited by

Periodical cited type(5)

1.	赵攀. 微通道经皮肾镜碎石取石术联合输尿管软镜钬激光碎石术治疗上尿路结石的效果观察. 大医生. 2025(01): 59-61 .
2.	李群秀，张胜利，邢伟只，李磊. 经皮肾微造瘘取石术联合输尿管软镜碎石术治疗上尿路结石患者的疗效观察. 实用临床医药杂志. 2024(10): 42-45 . 本站查看
3.	何泉芳，王沛昌，杨华旭，唐华，陈启富，王德明，林金松，林叶福. 闽西地区感染性结石的危险因素分析及预测模型构建. 实用临床医药杂志. 2024(10): 24-28+34 . 本站查看
4.	王纯才，刘近坤. 上尿路结石输尿管软镜手术与经皮肾镜碎石取石术治疗效果对比. 系统医学. 2023(08): 106-109 .
5.	张名清，刘芳，吴雯. 上尿路结石术后泌尿系感染患者的中段尿病原微生物培养结果及菌株耐药性分析. 实用医技杂志. 2023(12): 881-884 .

Other cited types(0)

Get Citation

PDF

XML

Article views PDF downloads Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Effect of immune score at initial diagnosis in predicting prognosis in patients with multiple myeloma treated with bortezomib